HMP has entered into drug discovery and development agreements with Johnson & Johnson, Eli Lilly, Merck KGaA and Procter & Gamble. In particular, the partnership between HMP and Johnson & Johnson marks the largest ever in the Chinese pharmaceutical industry, with upfront and milestone payments of up to $100 million.

Those partnerships validate our business model and quality of its drug discovery and development.  Our collaboration with large pharmaceutical companies represents a new model of innovative drug discovery & development partnerships for the Chinese pharmaceutical R&D industry.  This kind of risk/reward and IP sharing model could quickly advance China’s new drug R&D capability to global level.

In addition, HMP has formed research and strategic collaborations with renowned univerisities and institutes worldwide such as the University of California at Los Angeles, the Shanghai Institute of Materia Medica, the Genetic and Cell Biology Institute of North-Eastern Normal University, the Chinese University of Hong Kong, the University of Maryland and Cambridge University.  We will continue to investigate and discuss other potential alliances with appropriate organizations.

HMP is seeking opportunities to collaborate with leading universities, research institutes, and pharmaceutical and biotechnology companies in the following areas:

Joint drug discovery research

Mechanism of Action studies
 
Joint clinical development

In- and out-licensing drug candidates at various stages